Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.76 |
| ▸ | MMP3 | P08254 | 11/20 | 0.76 |
| ▸ | MMP9 | P14780 | 7/20 | 0.76 |
| ▸ | MMP7 | P09237 | 2/20 | 0.76 |
| ▸ | MMP2 | P08253 | 6/20 | 0.70 |
| ▸ | MMP8 | P22894 | 6/20 | 0.70 |
| ▸ | MMP13 | P45452 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MMP16 | P51512 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368493 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7368499 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7368495 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7708694 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7367838 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7367842 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7367840 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7369142 | 0.77 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7368395 | 0.77 | MMP1 (1.00) | MMP1MMP3MMP9MMP7MMP2 | |
| SCHEMBL7362322 | 0.76 | MMP1 (0.71) | MMP1MMP3MMP9MMP7MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP1 2/4885MMP3 11/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.